Showing results (71-80 of 193) with videos related to
Sort By:
Pageof 20
World Journal of Urology|June 30, 2020
An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitorsMatthew B Harrell, Kaylee Ho, Alexis E Te, et al.Reviews in Urology|November 14, 2013
Use of herbal supplements for overactive bladderBilal Chughtai, Elizabeth Kavaler, Richard Lee, et al.International Braz J Urol : Official Journal of the Brazilian Society of Urology|March 16, 2013
Noninvasive methods to evaluate bladder obstruction in menDean S Elterman, Bilal Chughtai, Richard Lee, et al.Therapeutic Advances in Urology|October 2, 2012
Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasiaBilal Chughtai, Dean S Elterman, Richard Lee, et al.BJU International|September 24, 2010
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trialSteven A Kaplan, Tim Schneider, Jenelle E Foote, et al.Urology|July 4, 2012
Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTSIan Milsom, Steven A Kaplan, Karin S Coyne, et al.Current Medical Research and Opinion|March 24, 2015
Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic reviewChristopher Chapple, Matthias Oelke, Steven A Kaplan, et al.Reviews in Urology|March 26, 2013
Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic HyperplasiaDean S Elterman, Bilal Chughtai, Richard K Lee, et al.Evidence-Based Complementary and Alternative Medicine : Ecam|December 3, 2005
Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndromeJillian L Capodice, Debra L Bemis, Ralph Buttyan, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 8, 2024
Long-term outcomes after treatment with Optilume BPH Four-year results from the EVEREST studySteven A Kaplan, Merycarla Pichardo, Edwin Rijo, et al.Pageof 20